Application of the International IgA Nephropathy Prediction Tool one or two years post-biopsy

Sean J. Barbour*, Rosanna Coppo, International IgA Nephropathy Network, Hong Zhang, Zhi Hong Liu, Yusuke Suzuki, Keiichi Matsuzaki, Lee Er, Heather N. Reich, Jonathan Barratt, Daniel C. Cattran*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

6 Citations (Scopus)
6 Downloads (Pure)


The International IgA Nephropathy (IgAN) Prediction Tool is the preferred method in the 2021 KDIGO guidelines to predict, at the time of kidney biopsy, the risk of a 50% drop in estimated glomerular filtration rate or kidney failure. However, it is not known if the Prediction Tool can be accurately applied after a period of observation post-biopsy. Using an international multi-ethnic derivation cohort of 2,507 adults with IgAN, we updated the Prediction Tool for use one year after biopsy, and externally validated this in a cohort of 722 adults. The original Prediction Tool applied at one-year without modification had a coefficient of variation (R2) of 55% and 54% and four-year concordance (C statistic) of 0.82 but poor calibration with under-prediction of risk (integrated calibration index (ICI) 1.54 and 2.11, with and without race, respectively). Our updated Prediction Tool had a better model fit with higher R2 (61% and 60%), significant increase in four-year C-statistic (0.87 and 0.86) and better four-year calibration with lower ICI (0.75 and 0.35). On external validation, the updated Prediction Tool had similar R2 (60% and 58%) and four-year C-statistics (both 0.85) compared to the derivation analysis, with excellent four-year calibration (ICI 0.62 and 0.56). This updated Prediction Tool had similar prediction performance when used two years after biopsy. Thus, the original Prediction Tool should be used only at the time of biopsy whereas our updated Prediction Tool can be used for risk stratification one or two years post-biopsy.

Original languageEnglish
Pages (from-to)160-172
Number of pages13
JournalKidney International
Issue number1
Publication statusPublished - 1 Jul 2022

Bibliographical note

Funding Information:
Funding support for this project was provided by grant funding from the Canadian Institutes of Health Research (PCG-155557). The European Validation Study of the Oxford Classification of IGA Nephropathy (VALIGA) study was supported by a grant from the first research call and the Immunonephrology Working Group of the European Renal Association – European Dialysis and Transplant Association. The Oxford derivation and North American Validation studies were supported by the International IgA Nephropathy Network, the Toronto GN Registry, and the Toronto General Hospital Foundation (McCann Fund). The funders had no role in the design or conduct of the study; the collection, management, analysis, or interpretation of the data; the preparation, review, or approval of the manuscript; or the decision to submit the manuscript for publication.

Publisher Copyright:
© 2022 International Society of Nephrology


Dive into the research topics of 'Application of the International IgA Nephropathy Prediction Tool one or two years post-biopsy'. Together they form a unique fingerprint.

Cite this